Alyeska Investment Group
EIGR

Alyeska Investment Group’s Eiger BioPharmaceuticals, Inc. EIGR Stock Holding History

Alyeska Investment Group’s Portfolio EIGR Stock Details EIGR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-1,667
Closed -$600K – 484
2018
Q3 		$600K Buy
+1,667
New +$570K 0.01% 372
2014
Q4 		– Sell
-32
Closed -$150K – 541
2014
Q3 		$150K Buy
+32
New +$169K ﹤0.01% 373

Other funds holding EIGR

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
IVM
InterWest Venture Management San Francisco, California $20.6M AUM 48.5% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
MP
Mangrove Partners Greenwich, Connecticut $1.24B AUM 41.74% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Alyeska Investment Group's EIGR Position: Q4 2018 in Review

Alyeska Investment Group sold out of Eiger BioPharmaceuticals, Inc. (EIGR) in Q4 2018, closing a stake of 1,667 shares — an estimated $600K sold.

Alyeska Investment Group first reported a position in EIGR in Q3 2014 and held it in 2 quarters. The position peaked at $600K in Q3 2018. 68 funds tracked by Wall St. Rank hold EIGR as of Q4 2018.

  • Alyeska Investment Group reported no remaining Eiger BioPharmaceuticals, Inc. position as of Q4 2018 after selling out during the quarter.
  • Alyeska Investment Group sold 1,667 Eiger BioPharmaceuticals, Inc. shares in Q4 2018, an estimated $600K.
  • Alyeska Investment Group first reported a position in Eiger BioPharmaceuticals, Inc. in Q3 2014 and held it in 2 quarters.
  • Alyeska Investment Group's Eiger BioPharmaceuticals, Inc. position peaked at $600K in Q3 2018.
  • 68 funds tracked by Wall St. Rank held Eiger BioPharmaceuticals, Inc. as of Q4 2018.

Based on Alyeska Investment Group's 13F filing for Q4 2018, filed 14 Feb 2019.